BM-1244

• Description:

  BM-1244 (APG-1252-M1) is a Bcl-xL/Bcl-2 inhibitor with Kis of 134 nM and 450 nM. BM-1244 has anti-tumor effects by inducing apoptosis and suppressing tumor growth. BM-1244 can induce cytochrome C and Smac release from mitochondria with caspase-3 and PARP cleavage. BM-1244 exhibits synergy with chemotherapy in vivo. BM-1244 can be studied in research for colorectal cancer, acute myeloid leukemia and gastric cancer[1][2][3].

• Product Name Alternative:

  APG-1252-M1

• UNSPSC:

  12352005

• Target:

  Apoptosis; Bcl-2 Family; Caspase; PARP

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bm-1244.html

• Concentration:

  10mM

• Purity:

  99.85

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)

• Smiles:

  O=C(C1CCN(CC[C@@H](NC2=CC=C(S(=O)(NC3=CC=C(N4CCN(C5=CC(F)=CC(C6=C(C7=CC=C(Cl)C=C7)N(C(C)C)C(C)=C6S(=O)(C)=O)=C5)CC4)C=C3)=O)C=C2S(=O)(C(F)(F)F)=O)CSC8=CC=CC=C8)CC1)O

• Molecular Formula:

  C54H59ClF4N6O8S4

• Molecular Weight:

  1159.79

• References & Citations:

  [1]Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005;333 (2) :336-343.|[2]Yi, H., et al., (2020) . Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer medicine, 9 (12), 4197-4206. |[3]Yao, W., et al., (2022) . Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis. Neoplasia (New York, N.Y.), 29, 100798.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1619923-32-8]